• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Arbro Pharmaceutical Limited (India) Grants Vanguard Pharmaceutical Corp. Exclusive Long Term Selling Contract in Latin America and Caribbean

Posted on: Thursday, 31 July 2008, 15:01 CDT

Vanguard Pharmaceutical Corp., (PINKSHEETS: VGPH) -- a company providing the market with affordable and safe generic medicines has been granted a 10 year exclusive sales contract from Arbro Pharmaceutical Limited for the sale of its pharmaceutical products in Latin America and the Caribbean.

Arbro has over 150 generic drugs that are regularly exported, is internationally accredited for Good Manufacturing Practices (GMP), follows the WHO guidelines, and is ISO 9001-2000 certified. Further, its internal testing labs provide a high standard of quality control and bioequivalence accreditation.

Vanguard's strategic alliance with Arbro will ensure delivery of high quality products at affordable prices. Vanguard has performed a market price analysis of Arbro's drugs in Brazil, Peru, and Paraguay and has found their prices to be significantly lower than recent tenders granting them a huge opportunity in these countries.

www.vanguardpharm.com

About Vanguard Pharmaceutical

In an era of ageing populations and rising health care costs. Vanguard's mission is to provide the market with drugs they can afford and with an assurance of its quality. To provide the market with affordable and safe drugs, Vanguard has focused on generic medicines. Generic medicines allow patients to access safe, effective, high-quality medicines at 10%-80% of the price of branded originator medicines. In this way, generic medicines support the sustainability of health care provision and contribute to controlling pharmaceutical expenditure.

Vanguard's main stream of business is the sale of generic drugs. It is currently targeting Latin America as it is believed to have a substantially unmet demand for advanced generics. The region is set to emerge as a globally significant market and its generics market is conservatively expected to reach US$6.4 billion by the year-end of 2009. Through its R&D facilities, Vanguard will strive to increase its generic product line further allowing them to penetrate Latin America and, in the future, expand into other geographic markets such as North America and Europe.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

 Contact: Francine Peres 210-215-4633 President Vanguard Pharmaceutical Corp. www.vanguardpharm.com

SOURCE: Vanguard Pharmaceutitcals Corp.

Source: MARKET WIRE

More News in this Category